drugset / Trial / NCT00472810

Ologen (OculusGen)-Glaucoma MMC Control in Pakistan

NCT00472810 ↗

Phase 3 Completed 40 enrolled Pro Top & Mediking Company Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the safety and effectiveness of the ologen (OculusGen) Biodegradable Collagen Matrix Implant and the MMC group in filtration surgery.

Timeline

Start
2007-03
Primary completion
2008-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Comparator MMC Unknown 0.2 mg/ml —
Comparator MMC Unknown 0.4 mg/ml —

Indications